DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Dr - 3 Eli Lilly - 2 ” - 2 Sanjay Gupta - 2 David Goodman - 2 Nick Stucky - 2 Mounjaro - 2 tirzepatide - 1
Top related locs:
Truveta Sweden U.S
Top related orgs:
CNN - 3 US Food and Drug Administration - 2 Novo Nordisk - 2 FDA - 2 CNN Health - 2 Drug - 2 Research - 2 semaglutide - 1

Search resuls for: "Truveta"


7 mentions found


☆ Mounjaro leads to significantly more weight loss than Ozempic, study suggests
  + stars: | 2024-07-08 | by ( Deidre Mcphillips | ) edition.cnn.com   time to read: +4 min
CNN —People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study. But 82% of people taking tirzepatide reached this important clinical benchmark, compared with about 67% of those taking semaglutide. Average weight loss was also consistently higher among those taking tirzepatide over time. And by one year, average weight loss was nearly double for those taking tirzepatide — more than 11%, compared with about 6% for those taking semaglutide. According to the new study, individuals with type 2 diabetes had less significant weight loss than those without a diagnosis — but average weight loss was still greater among those taking tirzepatide.
Persons: tirzepatide, Eli Lilly, ”, Dr, Sanjay Gupta, CNN’s Brenda Goodman Organizations: CNN, US Food and Drug Administration, Novo Nordisk, semaglutide, FDA, CNN Health Locations: Truveta
☆ The Adderall shortage highlights a key issue for voters in 2024. Here's what the Biden Administration is doing about it.
  + stars: | 2024-04-12 | by ( Allie Kelly | ) www.businessinsider.com   time to read: +6 min
Adderall supply issues, which began in October 2022, are making the medication more expensive. The Biden Administration said it's focused on strengthening manufacturing supply chains for Adderall. AdvertisementIt's been 18 months since the US Food and Drug Administration announced an Adderall shortage. The prescription fill rate for ADHD medications fell from 44.5% in December 2022 to 40.7% in February 2023, the study found. Have you been impacted by the Adderall shortage or high prescription drug costs?
Persons: it's, —, It's, Biden, Biden's, Joe Biden's, Adderall —, aren't, Dr, David Goodman Organizations: Biden Administration, Service, Food and Drug Administration, KFF, Kaiser Family Foundation, Business, Drug, Biden's Administration, Department of Health, Human Services, Defense, FDA, CNN, USA, DEA, USA Today, Johns Hopkins University, Medscape Medical, Government
☆ CNN Exclusive: Adderall prescriptions have been filled less often amid ongoing shortage in the US
  + stars: | 2024-04-02 | by ( Deidre Mcphillips | ) edition.cnn.com   time to read: +10 min
CNN —About 1 in every 10 people in the US who uses Adderall or similar combination drugs to treat attention-deficit/hyperactivity disorder (ADHD) has been affected by an ongoing shortage, a new analysis suggests. The US Food and Drug Administration announced that Adderall was in shortage in mid-October 2022, and the share of people with ADHD who filled their prescriptions for Adderall and related medications plunged in the following months. Patients were considered eligible for a monthly prescription fill if they had filled one within the previous two years. Prescriptions for medications used to treat ADHD surged during the Covid-19 pandemic, especially among young adults and women, one study found. But it’s been about a year and a half since she’s been able to fill her Adderall prescription in a “totally uneventful” way, she said.
Persons: Adderall, Robert Califf, Anne Milgram, David Goodman, ”, Mary Beth King, it’s, she’s, ” King, King, ” Goodman, John Mitchell, ” Mitchell, they’re, ’ ”, –, “, Dr, Sanjay Gupta, hasn’t Organizations: CNN, US Food and Drug Administration, Drug, of Psychiatry, Behavioral Sciences, Johns Hopkins School of Medicine, American Professional Society, New, Psychiatric Institute, Columbia University Irving Medical Center, Duke University School of Medicine, Get CNN, CNN Health Locations: Sweden
☆ Study finds Mounjaro outperforms Ozempic in overweight & obese adults: Truveta's VP of Research
  + stars: | 2023-11-27 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailStudy finds Mounjaro outperforms Ozempic in overweight & obese adults: Truveta's VP of ResearchDr. Nick Stucky, VP of Research at Truveta, joins 'Fast Money' to talk the results of a study comparing weight-loss drugs Mounjaro and Ozempic.
Persons: Mounjaro outperforms, Nick Stucky, Mounjaro Organizations: Research
☆ Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says
  + stars: | 2023-11-27 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
The blockbuster diabetes drug Mounjaro is more effective for weight loss than another highly popular treatment, Ozempic, in overweight or obese adults, according to a large analysis of real-world data published Monday. The results come as both drugs and similar treatments approved for weight loss soar in demand in the U.S. for their ability to help patients shed unwanted pounds over time. Previous head-to-head studies have similarly suggested that Mounjaro is more effective than Ozempic for weight loss and controlling blood sugar in adults with Type 2 diabetes. But Monday's study confirms Mounjaro's edge over Ozempic in a real-world setting, specifically among adults who are overweight or obese. Eli Lilly is pitting Mounjaro against Wegovy, a higher-dose version of Ozempic approved for weight loss, in an ongoing clinical trial in obese or overweight patients.
Persons: Eli Lilly, Mounjaro, We've, Nick Stucky Organizations: Novo Nordisk, Truveta Research, Research, Wegovy Locations: U.S
☆ 'It totally backfired': The pitfalls of Alzheimer's genetic testing
  + stars: | 2023-04-21 | by ( Julie Steenhuysen | ) www.reuters.com   time to read: +8 min
CHICAGO, April 21 (Reuters) - Wendy Nelson watched her mother slowly die of Alzheimer's disease, unable to move or swallow at the end. When her father's memory began to fail a year later, one of her two sisters doubted it could be Alzheimer's, Nelson said. THE TESTING REVOLUTIONUntil recently, most doctors tended not to order genetic tests to determine Alzheimer's risk, because there were no effective treatments to slow or prevent the disease. US regulators recommend genetic testing before starting treatment with Leqembi. Some members of families with increased genetic risk of Alzheimer's say it might be better not to know at all.
☆ 'They are untouchable': Microsoft employees say 'golden boy' executives are still running wild, 8 years after the company vowed to clean up its toxic culture
  + stars: | 2022-11-24 | by ( Ashley Stewart | ) www.businessinsider.com   time to read: +23 min
The Microsoft executive walked into the small, windowless room in Studio C at about 8 o'clock that evening. Despite Nadella's public stance against those he has called "talented jerks," many inside the company say Microsoft retains a nearly unlimited tolerance for bad behavior by its top rainmakers and developers. "The Microsoft of 2021 is very different from the Microsoft of 2000 to me and to everyone at Microsoft," Nadella said. But some women say the investigations drag on for months or even years, with no clear timeline for resolution. What's more, some employees say Microsoft's efforts to promote racial equity often smack of tokenism.
0 next >>
Total: 7